Gottlieb Brings VC Toolkit to FDA

Gottlieb Brings VC Toolkit to FDA

Soon-to-be FDA commissioner, Scott Gottlieb, MD, is well positioned to understand where the medtech and biotech communities are coming from. He’s been a partner at the venture capital fund New Enterprise Associates since he left the FDA in 2007, where he served as deputy FDA commissioner under President George W. Bush, and performed a stint…

Read More

Allergan Makes a Play in Gene Editing

With its licensing agreement to develop genome-editing programs with Editas Medicine to treat retinal diseases, Allergan has made a move to partner with one of the leading players in the CRISPR genome-editing space at a time when the field is poised to take off. That’s not Allergan’s hype. A recent report by San Francisco-based Grand…

Read More

Is DR Just the Start for Google Brain?

A team of investigators recently reported online in the Journal of the American Medical Association1 that a Google algorithm allows computers to diagnose diabetic retinopathy (DR) using retina photos. The technology will never replace doctors, but Google hopes it will assist them, especially in underserved areas. Google’s first priority with this technology is to distribute…

Read More

Encore Vision Delivers Big Payday to Angel Investors

Big winners in Novartis AG’s acquisition of Encore Vision for $465 million are members of a network of angel investors in Fort Worth, TX, that bet $4 million on the presbyopia-correcting eye drop that Encore Vision president and CEO Bill Burns has been working on for about nine years. The $4 million the Cowtown Angels…

Read More

Google–Moorfields Venture Eyes AI to Speed Diagnosis with OCT

Google–Moorfields Venture Eyes AI to Speed Diagnosis with OCT

Google’s DeepMind Health artificial intelligence project and Moorfields Eye Hospital in London have teamed up for a five-year venture to develop an algorithm using one million anonymized retina scans from the Moorfields’ database to speed up and improve diagnosis of age-related macular degeneration (AMD) and diabetic retinopathy. Google and Moorfields announced the collaboration this month.…

Read More

Bausch + Lomb’s CMO Cal Roberts on How He Uses His MD & Experience to Build the Right Tool Kit for Ophthalmologists

Bausch & Lomb’s CMO Cal Roberts on How He Uses His MD and Experience to Build the Right Tool Kit for Ophthalmologists - OIS Podcast - Eye On Innovation - Healthegy

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 088″] Bausch + Lomb’s chief medical officer Calvin Roberts, MD, still thinks like a doc when he’s helping to steer the company’s strategy. Hear how he sees B+L making life simpler for ophthalmologists in the near future. Podcast Guest Calvin W. Roberts, MD Calvin W. Roberts, MD, is Executive Vice President…

Read More

Zeiss CEO Monz on Building a Really Strong Brand

Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG, shares how his company’s long history in ophthalmology helps it pave a path for new markets and technologies. Video Highlights 00:34 – How much of Carl Zeiss is ophthalmology? 01:00 – In ophthalmology we try to provide everything needed for diagnosis and treatment. 01:30…

Read More

B&L’s Roberts Still Thinks Like a Doctor

Calvin Roberts, MD, CMO at Bausch & Lomb lends his physician’s perspective to how companies like Bausch & Lomb can serve eye care. Video Highlights 00:42 – I’m always asking what can we do for patient and what can we do for doctors? 01:00 – Think of all the things we do today for doctors…

Read More

New CEO Boorady Explains TearScience’s Strategic Shift

TearScience, the device company focused on the role of the meibomian glands in dry eye, has pivoted its business model to concentrate more on early-stage meibomian gland dysfunction (MGD) with the LipiFlow thermal pulsation device and high-definition imaging of the meibomian glands. Highlights 00:39 – When did you join TearScience and what changes did you…

Read More

Mynosys Eye Commercial Launch of Zepto

Zepto represents an “innovative, disposable capsulotomy device,” said president and CEO John Hendrick. It does not disrupt the natural flow of cataract procedures or patient flow. Its proprietary cutting edge doesn’t burn tissue (no cautery, thermal burning), but instead cleaves the tissue, providing an “unusual edge to the capsulotomy,” he explained. Finally, the device requires…

Read More

Five Novel Innovations from WTF@OIS

The “What’s the Future@OIS” session at OIS@ASCRS 2016 showcased five novel innovations in ophthalmology that are difficult to place into any existing categories of ophthalmic devices and drugs. Here’s a quick look at them. Depressurizing goggles for glaucoma. Equinox is developing the Balance Goggles, which create a small vacuum on the eyes for people with…

Read More